TY - JOUR
T1 - Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline
T2 - Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring
AU - Capiau, Sara
AU - Veenhof, Herman
AU - Koster, Remco A.
AU - Bergqvist, Yngve
AU - Boettcher, Michael
AU - Halmingh, Otto
AU - Keevil, Brian G.
AU - Koch, Birgit C. P.
AU - Linden, Rafael
AU - Pistos, Constantinos
AU - Stolk, Leo M.
AU - Touw, Daan J.
AU - Stove, Christophe P.
AU - Alffenaar, Jan-Willem C.
N1 - Funding Information:
Received for publication November 29, 2018; accepted March 16, 2019. From the *Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; †Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ‡PRA Health Sciences, Bioana-lytical Laboratory, Assen, the Netherlands; §Professor Emeritus, Dalarna University College, Borlänge, Sweden; ¶MVZ Labor Dessau GmbH, Dessau-Roßlau, Germany; ║Spark Holland BV, Emmen, the Netherlands; **Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; ††Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands; ‡‡Laboratory of Analytical Toxicology, Institute of Health Sciences, Universidade Feevale, Novo Hamburgo, Brazil; §§Department of Chemistry, West Chester University, West Chester, Pennsylvania; ¶¶Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands; ║║Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands; ***School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; and †††Westmead Hospital, Sydney, Australia. The artwork was financially supported by the IATDMCT, UGent, and UMCG. Furthermore, S. Capiau wishes to acknowledge the FWO Research Foundation Flanders for granting her a PhD fellowship (application number 11R7316N). The authors declare no conflict of interest. S. Capiau, H. Veenhof, D. Touw, C. Stove, J.-W. Alffenaar are equally contributed. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.drug-monitoring.com). Correspondence: Jan-Willem Alffenaar, PhD, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands (e-mail: j.w.c. [email protected]). Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Dried blood spot (DBS) analysis has been introduced more and more into clinical practice to facilitate Therapeutic Drug Monitoring (TDM). To assure the quality of bioanalytical methods, the design, development and validation needs to fit the intended use. Current validation requirements, described in guidelines for traditional matrices (blood, plasma, serum), do not cover all necessary aspects of method development, analytical- and clinical validation of DBS assays for TDM. Therefore, this guideline provides parameters required for the validation of quantitative determination of small molecule drugs in DBS using chromatographic methods, and to provide advice on how these can be assessed. In addition, guidance is given on the application of validated methods in a routine context. First, considerations for the method development stage are described covering sample collection procedure, type of filter paper and punch size, sample volume, drying and storage, internal standard incorporation, type of blood used, sample preparation and prevalidation. Second, common parameters regarding analytical validation are described in context of DBS analysis with the addition of DBS-specific parameters, such as volume-, volcano-and hematocrit effects. Third, clinical validation studies are described, including number of clinical samples and patients, comparison of DBS with venous blood, statistical methods and interpretation, spot quality, sampling procedure, duplicates, outliers, automated analysis methods and quality control programs. Lastly, cross-validation is discussed, covering changes made to existing sampling- and analysis methods. This guideline of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology on the development, validation and evaluation of DBS-based methods for the purpose of TDM aims to contribute to high-quality micro sampling methods used in clinical practice.
AB - Dried blood spot (DBS) analysis has been introduced more and more into clinical practice to facilitate Therapeutic Drug Monitoring (TDM). To assure the quality of bioanalytical methods, the design, development and validation needs to fit the intended use. Current validation requirements, described in guidelines for traditional matrices (blood, plasma, serum), do not cover all necessary aspects of method development, analytical- and clinical validation of DBS assays for TDM. Therefore, this guideline provides parameters required for the validation of quantitative determination of small molecule drugs in DBS using chromatographic methods, and to provide advice on how these can be assessed. In addition, guidance is given on the application of validated methods in a routine context. First, considerations for the method development stage are described covering sample collection procedure, type of filter paper and punch size, sample volume, drying and storage, internal standard incorporation, type of blood used, sample preparation and prevalidation. Second, common parameters regarding analytical validation are described in context of DBS analysis with the addition of DBS-specific parameters, such as volume-, volcano-and hematocrit effects. Third, clinical validation studies are described, including number of clinical samples and patients, comparison of DBS with venous blood, statistical methods and interpretation, spot quality, sampling procedure, duplicates, outliers, automated analysis methods and quality control programs. Lastly, cross-validation is discussed, covering changes made to existing sampling- and analysis methods. This guideline of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology on the development, validation and evaluation of DBS-based methods for the purpose of TDM aims to contribute to high-quality micro sampling methods used in clinical practice.
KW - dried blood spots
KW - guideline
KW - validation
KW - microsampling
KW - VAMS
KW - HEMATOCRIT-INDEPENDENT RECOVERY
KW - LC-MS/MS
KW - QUANTITATIVE-DETERMINATION
KW - BIOANALYTICAL METHODS
KW - MASS-SPECTROMETRY
KW - CYCLOSPORINE-A
KW - REGRESSION PROCEDURES
KW - TRANSPLANT PATIENTS
KW - EBF RECOMMENDATION
KW - ALTERNATIVE TOOL
U2 - 10.1097/FTD.0000000000000643
DO - 10.1097/FTD.0000000000000643
M3 - (Systematic) Review article
C2 - 31268966
SN - 0163-4356
VL - 41
SP - 409
EP - 430
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 4
ER -